This was significant only for the KU55933 manufacturer baseline BMD at the hip (p < 0.05). In the group of patients with a new non-vertebral fracture, more patients used ART than
in the group without a new non-vertebral fracture (62% versus 24%, p < 0.05). When comparing patients with and without incident vertebral fractures, there were significantly more patients using corticosteroids (78% versus 54%) in the patients with a new vertebral fracture during follow-up (p < 0.05). Patients with new vertebral fractures had also suffered significantly more non-vertebral Histone Methyltransferase inhibitor fractures at baseline (p < 0.05), but seemed to have less vertebral fractures at baseline (p = 0.067). There was also a trend for a higher disease activity (mean CRP during follow-up and DAS-28 at baseline) in the patients with a new vertebral fracture compared to patients without a new vertebral fracture (Table 2). Table 2 Demographics and disease variables for patients with and without new vertebral and non-vertebral fractures baseline or follow-up Vertebral fracture Non-vertebral fracture Yes (18) No (79) p Yes (16) No (86) p Age, years Mean (SD) 61 (6.5) 60 (5.8) 0.49 62 (5.0) 60 (6.1) 0.20 Disease duration, years Mean (SD) 17 (8.7) 17 (10.5)
0.95 18 (8.7) 17 (10.7) 0.70 IgM-RF positive N (%) 9 (50) 24 (30) 0.278 10 (62) 57 (67) 0.77 BMI, kg/m2 Mean (SD) 25.1 (3.8) 25.1 (4.0) 0.96 24.7 (2.9) 25.6 (5.1) selleck chemicals llc 0.27 HAQ Mean (SD) 1.56 (0.35) 1.4 (0.72) 0.30 1.4 (0.75) 1.5 (0.68) 0.79 Use of corticosteroids N (%) 14 (78) 43 (54) 0.04 11 (69) 47 (54) 0.30 Use of ART during follow-up N (%) 7 (39) 24 (30) 0.49 10 (62) 21 (24) 0.002 Regorafenib BMD spine, g/cm2 at baseline Mean (SD) 0.981 (0.193) 1.159 (0.516) 0.12 0.969 (0.132) 1.151 (0.585) 0.08 BMD hip, g/cm2 at baseline Mean (SD) 0.843 (0.138) 0.840 (0.165) 0.96 0.751 (0.108) 0.858 (0.159) 0.003 DAS-28 at baseline Mean (SD) 5.2 (0.7) 4.7 (1.2) 0.06 4.8 (1.2) 4.8 (1.2) 0.89 Mean ESR, mm/h Mean (SD) 22.3 (13.3) 20.1 (11.5) 0.49 21.7 (13.6) 20.8 (11.6) 0.80
Mean CRP, mg/L Mean (SD) 15.7 (8.0) 11.3 (8.1) 0.07 12.5 (6.4) 12.7 (11.7) 0.82 Vertebral fracture at baseline N (%) 1 (5) 11 (15) 0.067 5 (31) 19 (22) 0.44 Non-vertebral fracture at baseline N (%) 8 (44) 15 (19) 0.02 4 (25) 10 (11) 0.12 Of the patients who were osteopenic at baseline, seven (19%) sustained a new vertebral fracture and six (17%) a new non-vertebral fracture during follow-up. In the group of osteoporosis patients, there were seven (27%) new vertebral and seven (27%) new non-vertebral fractures during follow-up.